More than two decades after the September 11 attacks, new research suggests that responders who worked amid the World Trade Center (WTC) dust and debris face nearly a 3-fold higher incidence of lung ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Lung cancer remains the leading cause of cancer-related death in the United States. The good news is that early detection ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant ...

Spotting ILDs may be challenging. Symptoms such as a dry cough, shortness of breath, and unexplained weight loss may go ...

Indiana farmers are expected to harvest 10.6 million acres of corn and soybeans this fall, powering the state’s agri-industry ...

Trodelvy reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The median progression-free survival ...

Zipalertinib showed efficacy in NSCLC with EGFR exon 20 insertions, achieving a 31.3% intracranial ORR and a 27.6% systemic ORR. The drug demonstrated a favorable safety profile, with low rates of ...

In light of new data at ESMO, researchers debated whether HER2-targeted tyrosine kinase inhibitors or antibody-drug conjugates might be better as initial treatment.

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

Positive results for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations were reported yesterday at the European Society for Medical Oncology ...